Cargando…
Sublingual immunotherapy tablet for the treatment of house dust mite allergic rhinitis in Canada: an alternative to minimize treatment costs?
BACKGROUND: A cost-minimization analysis (CMA) was performed to estimate the economic impact of introducing the SQ house dust mite sublingual immunotherapy (SQ HDM SLIT)-tablet marketed as ACARIZAX™ (regulatory approval May 2017) for the treatment of HDM-induced allergic rhinitis in Canada (Ontario...
Autores principales: | Ellis, Anne K., Gagnon, Rémi, Hammerby, Eva, Lau, Andrea |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6487002/ https://www.ncbi.nlm.nih.gov/pubmed/31061666 http://dx.doi.org/10.1186/s13223-019-0344-3 |
Ejemplares similares
-
Sublingual immunotherapy tablet: a cost-minimizing alternative in the treatment of tree pollen-induced seasonal allergic rhinitis in Canada
por: Ellis, Anne K., et al.
Publicado: (2021) -
House dust mite sublingual tablet is effective and safe in patients with allergic rhinitis
por: Okamoto, Y., et al.
Publicado: (2016) -
157 The Post-Treatment Efficacy of House Dust Mite Sublingual Allergen Immunotherapy Tablets in Adults With Allergic Rhinitis
por: Bergmann, Karl-Christian, et al.
Publicado: (2012) -
Outcome of Sublingual Immunotherapy in Patients With Allergic Rhinitis Sensitive to House Dust Mites
por: Kim, Seon-Tae
Publicado: (2015) -
Efficacy and safety of house dust mite sublingual immunotherapy tablets in allergic rhinitis: A systematic review and meta-analysis
por: Kulalert, Prapasri, et al.
Publicado: (2022)